Women on blockbuster weight loss drugs warned to use effective contraception
The UK Medicines and Healthcare products Regulatory Agency (MHRA) also said women should not take weight loss drugs if they are breastfeeding or trying to get pregnant, because there isn't enough safety data to know whether the medicine could affect their baby.
'Anyone who gets pregnant while using them should speak to their healthcare professional and stop the medicine as soon as possible,' the agency said.
Meanwhile, all women taking the jabs should ensure they are using a form of contraception that works, the MHRA said.
Related
Weight-loss drugs like Wegovy could help serious liver condition that has no cure-all treatment
One of the drugs, Mounjaro, may make birth control pills less effective, so the agency says women taking the jab should also use a non-oral form of contraception, like an implant or intrauterine device (IUD).
'Obesity reduces fertility in women. So, women with obesity taking GLP-1 drugs are more likely to get pregnant than before they lost weight,' Dr Channa Jayasena, a reproductive endocrinology researcher at Imperial College London, said in a statement.
'Women are advised to do all they can to prevent pregnancy while taking [these] drugs,' Jayasena added.
Related
France won't pay for weight loss drug Wegovy. What about other European countries?
In the UK, women already receive these warnings when they get their prescriptions for the blockbuster jabs, which include Ozempic, Wegovy, Saxenda, and Victoza as well as Mounjaro.
The drugs, known as GLP-1 receptor agonists, work by mimicking hormones that help regulate appetites and make people feel full for longer. They have been approved to treat type 2 diabetes and obesity.
Related
Why are 1 in 10 French women still smoking during pregnancy despite the health risks?
But the MHRA issued the reminder Thursday due to concerns that the drugs' growing popularity means women are buying them illegally online or at beauty salons, without seeing a doctor.
'Skinny jabs are medicines licensed to treat specific medical conditions and should not be used as aesthetic or cosmetic treatments,' Dr Alison Cave, MHRA's chief safety officer, said in a statement.
'They are not a quick fix to lose weight and have not been assessed to be safe when used in this way,' she added.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hill
26 minutes ago
- The Hill
Copycat Ozempic, Mounjaro proliferate even in postshortage era
Copycat versions of popular drugs like Ozempic and Mounjaro have continued to proliferate in a postshortage era, with some experts saying 'regulatory neglect' is allowing for potentially dangerous, unapproved drugs to reach consumers. When the Food and Drug Administration (FDA) adds a drug to its official shortage list, compounding pharmacies can sell their own versions of that drug so patients can continue to access medications. This was the case when weight loss drugs like tirzepatide and semaglutide went into shortage due to high demand. Online companies like Hims & Hers and Ro entered the GLP-1 market with compounded versions of Wegovy and Zepbound. These medications contain the same active pharmaceutical ingredient as the branded version but are formulated slightly differently, such as altering a medication for a patient who can't swallow pills. Due to the often highly individualized nature of compounded drugs, they are not FDA-approved. But although the FDA has since removed these drugs from its shortage list, stakeholders say compounded drugs continue to be sold, and lawmakers in Congress have begun raising concerns with federal regulators. There are two types of compounding pharmacies, 503A and 503B. 503A compounding pharmacies fulfill personalized, patient-specific prescriptions. 503B compounding pharmacies can do the same while also fulfilling bulk orders for clients like hospitals. Prior to the end of the shortage, telehealth companies primarily relied on 503B compounders, but according to those in the drug space, online sellers are turning to 503A compounders to keep the lucrative business going. Novo Nordisk, the manufacturer of semaglutide, partnered with Hims & Hers to sell a low-cost version of its branded product Wegovy after the shortage officially ended. But that partnership was dissolved after Novo Nordisk accused Hims & Hers of illegally continuing to sell compounded versions of its drug 'under the false guise of personalization.' Experts in the field say the maneuver falls into a regulatory 'gray area.' 'I hesitate to even call these people compounders. Because what they really are are illegal pharmaceutical companies,' said Peter Pitts, former FDA associate commissioner and president of the Center for Medicine in the Public Interest. 'You don't compound for tens of millions of people, and you don't personalize for tens of millions of people. That's just kind of a fake brand extension.' In July, a bipartisan coalition of House lawmakers sent a letter to FDA Commissioner Marty Makary asking that he direct his agency to address the flow of illicit anti-obesity medications (AOM) into the country. While not specifically focused on compounded drugs, the letter did note the possibility for ambiguity between these medications and illicitly sourced drugs. 'We understand the distinction between legitimate compounded drugs prepared in state-licensed pharmacies and counterfeit or compounded drugs made from illicit ingredients obtained from illegitimate sources,' wrote the lawmakers. 'However, unapproved AOMs continue to be widely marketed online, in print, and on television.' Sen. Marsha Blackburn (R-Tenn.) sent a letter to the Federal Trade Commission in July, calling for the agency's action on online advertising of compounded GLP-1s. She was reiterating warnings that a bipartisan group of state attorneys general had made. 'Amid the unprecedented demand for these miracle medicines, foreign criminals and con artists are defrauding and endangering Americans by selling and shipping counterfeit or deceptively-marketed GLP-1 drugs and active ingredients,' she wrote. A spokesperson for Ro said the company 'does not market or advertise compounded GLP-1s.' The Hill was able to find a half-dozen lower-profile companies still marketing compounded GLP-1s online. Hims & Hers, perhaps the most well-known of these online companies, disputed Pitt's characterization. 'Anyone claiming that we compound personalized medications for tens of millions of people is simply wrong and is mischaracterizing our business. We follow the carefully written compounding regulations and only offer access to compounded treatments when a licensed provider determines it is clinically necessary, in their independent judgment, for their individual patient,' the company said in a statement to The Hill. 'That's the future of healthcare: a system centered on the individual where providers have a way to treat the individual in front of them.' The Federal Trade Commission declined to comment as its investigations are nonpublic. The FDA did not respond to a request for comment. Pitts expressed incredulity that federal regulators hadn't stepped in already, saying, 'How long can the FDA permit kind of regulatory neglect, to allow this problem just to snowball until they get engaged?' Although the continued sale of compounded GLP-1s falls into a regulatory gray area, Pitts believes it goes against the 'spirit' of the regulations. He further cited the '5 percent rule' for compounding pharmacies, which dictates that the percentage of compounded drugs that a pharmacy distributes out of state not exceed 5 percent, saying online sellers have exceeded this rule by '10,000-fold.' According to recent polling, consumers are concerned about where compounded drugs originate from. A poll conducted by the firm Fabrizio Ward, run by President Trump's 2024 campaign pollster Tony Fabrizio, found that 64 percent of surveyed voters don't believe compounders should be able to continue to make drugs outside of the current legally permitted circumstances. Voters in the survey were split when asked how confident they were that online pharmacies sold safe, FDA-approved drugs, with 46 percent saying they were confident and 41 percent saying they were not. A majority of voters — 78 percent — said they had concerns about bulk, compounded versions of drugs like Wegovy and Zepbound coming into the U.S. from overseas sources. During the active shortage of GLP-1 products, questions were raised over where compounding pharmacies were sourcing the active pharmaceutical ingredients for their products. Telehealth companies have said their products come from FDA-regulated facilities. 'There's a difference between a product being made in an FDA-approved facility and a product being manufactured on an FDA-approved line for that product,' said Pitts. 'The FDA does not inspect production lines for illegal manufacturing, that just does not happen. So, it's an entirely fake proposition.'
Business Insider
4 hours ago
- Business Insider
Why Is Catheter Precision Stock (VTAK) Up 70% Today?
Catheter Precision (VTAK) stock saw major gains on Monday after the medical device company's LockeT was registered and approved in the UK. This was the final step needed to begin sales of the suture retention device in the UK after it received a CE Mark for European approval and distribution in May 2025. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Catheter Precision will sell LockeT through UK-based value-added distributor HC21. The company has already worked with this distributor for years, selling other products in the region. This agreement was updated to include sales of LockeT. Fatih Ayoglu, Catheter Precision Sales Manager EMEA & APAC, said, 'We are proud to announce the approval of LockeT for use in the United Kingdom, marking a significant milestone in our mission to support healthcare systems with innovative, patient-centric solutions. With the NHS recently achieving its first reduction in waiting lists in 17 years, LockeT is poised to contribute meaningfully to this momentum by helping clinicians deliver more treatments, more efficiently.' Catheter Precision Stock Movement Today Catheter Precision stock was up 72.03% in pre-market trading on Monday, following a 10.74% fall on Friday. The company's shares have also declined 69.54% year-to-date and 93.78% over the past 12 months. Today's movement came with heavy trading, as some 23 million shares changed hands, compared to a three-month daily average of about 92,000 units. Is Catheter Precision Stock a Buy, Sell, or Hold? Turning to Wall Street, coverage of Catheter Precision stock is thin. Fortunately, TipRanks' AI analyst Spark has it covered. Spark rates VTAK stock a Neutral (41) with no price target. It cites 'significant financial and operational challenges with ongoing losses and negative cash flow' as reasons for this stance.
Yahoo
4 hours ago
- Yahoo
Novo Nordisk (NVO) Receives FDA Approval for Wegovy
Novo Nordisk (NYSE:NVO) is one of the Most Profitable Large Cap Stocks to Buy According to Analysts. On August 15, Novo Nordisk (NYSE:NVO) announced that the FDA had approved the use of its new drug Wegovy to treat adults with noncirrhotic metabolic dysfunction-associated steatohepatitis. The drug also moderates advanced liver fibrosis. The approval follows positive results from the ESSENCE trial, where the drug depicted better results compared to the placebo. At week 72, 36.8% of patients taking Wegovy improved their liver fibrosis without worsening steatohepatitis. Whereas the placebo only improved results in 22.4% of the patients. With the approval, Wegovy is now the first and only GLP-1 drug approved for noncirrhotic metabolic dysfunction-associated steatohepatitis. An elderly couple receiving insulin from a pharmacist, representing healthcare company's successful pharmaceutical products. Novo Nordisk (NYSE:NVO) is a global healthcare company specializing in diabetes and obesity care. While we acknowledge the potential of NVO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
